Alexion $930 million acquisition of Achillion

Overview:

• Massachusetts based biopharmaceutical company Alexion reached an agreement to buy clinical stage biopharmaceutical company Achillion for $930 million.
• The initial purchase price is equivalent to $6.30 per share of Achillion common stock, a 73% premium. Achillion shareholders are eligible to receive an additional $2 per share subject to the company meeting certain clinical and regulatory milestones.
• Centerview Partners acted as the exclusive financial advisor to Achillion.
• The transaction will be funded with cash and is expected to close in the first half of 2020, subject to shareholder approval and customary closing conditions.

Chynna Lewis – Researcher